Legal status by country
Is Anti-IL-11 legal?
Written by Aaron CuhaReviewed Sep 2026
How Anti-IL-11 is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Investigational, not approved | Investigational, not licensed | Investigational, not registered | Investigational, not approved |
| Note | No anti-IL-11 agent is approved. Early human development targets fibrotic disease rather than ageing. Note that recombinant IL-11 was itself once an approved drug, for the opposite purpose. | None recorded | None recorded | None recorded |
US FDA status: No anti-IL-11 agent is approved for any indication. Recombinant IL-11 itself, oprelvekin, was previously an approved drug for thrombocytopenia, which is the opposite intervention.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.